Latest Stent Stories

Brajesh K. Lal, M.D., lead author and associate professor of vascular surgery at the University of Maryland School of Medicine in Baltimore and chief of vascular surgery at the Baltimore VA Medical Center found that two years after treatment with either surgery or stents, reblockage of arteries remained the same. Baltimore, MD (PRWEB) February 01, 2012 A new comparison of the procedures to help prevent strokes by removing or relieving blockages in the arteries of the neck concludes they...

University of Maryland-led comparative study may challenge standard of care A new comparison of the procedures to help prevent strokes by removing or relieving blockages in the arteries of the neck concludes they are equally effective at halting repeat blockage. Two years after treatment with either surgery or a minimally invasive treatment using wire coils called stents, the re-blockage rate remained the same, approximately six percent. Results of the analysis were detailed in a...

University of Maryland-led comparative study may challenge standard of care BALTIMORE, Feb. 1, 2012 /PRNewswire-USNewswire/ --A new comparison of the procedures to help prevent strokes by removing or relieving blockages in the arteries of the neck concludes they are equally effective at halting repeat blockage. Two years after treatment with either surgery or a minimally invasive treatment using wire coils called stents, the re-blockage rate remained the same,...

Opening blocked neck arteries with a metal stent or surgery were equally durable, in research presented at the American Stroke Association's International Stroke Conference 2012. Two years after the procedures, less than 7 percent of patients had developed repeat blockages (restenosis), researchers said. "Unlike bare metal stents placed in coronary arteries, where re-blockage occurs about 20 percent of the time, we found the re-blockage rates in the carotid artery were quite small,"...

NATICK, Mass., Feb. 1, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces first patient use and European market launch of the PROMUS Element(TM) Plus Everolimus-Eluting Platinum Chromium Coronary Stent System. The first patient implant in Europe using the new device was performed by Professor Antonio Colombo, M.D., Director of the Cardiac Catheterization Laboratory at Columbus Hospital and San Raffaele Hospital in Milan, Italy. The new stent system...

TEL AVIV, Israel, Jan. 31, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced the appointment of Dr. James Barry to its Board of Directors as an independent director. Dr. Barry is an experienced medical technology executive and former senior executive at...

CLEVELAND, Jan. 24, 2012 /PRNewswire/ -- Physicians at University Hospitals (UH) Case Medical Center enrolled their first patient in LEVANT 2, a global, multicenter, randomized clinical trial evaluating the safety and efficacy of the Moxy(TM) Drug Coated Balloon for the treatment of peripheral arterial disease (PAD). Co-investigators Sahil Parikh, MD, Michael Cunningham MD, and Vikram Kashyap, MD, with UH Harrington-McLaughlin Heart & Vascular Institute at UH Case Medical...

New findings from a research study led by physicians at Scripps Health reveal that the drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications. Initial results from the BRIDGE trial will be published Jan. 18, 2012, in an article in the Journal of the American Medical Association...

SAN DIEGO, Jan. 17, 2012 /PRNewswire/ -- New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications. Initial results from the BRIDGE trial will be published Jan....

NATICK, Mass. and MIAMI, Jan. 16, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the Company's Epic(TM) Self-Expanding Nitinol Stent System in patients with iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow. Results were presented today by Daniel Clair, M.D., FACS, Principal...